RESUMEN
Two women who developed tumour progression while taking anti-oestrogens are described and some of the possible mechanisms for this action are discussed.
Asunto(s)
Neoplasias de la Mama/patología , Nafoxidina/efectos adversos , Pirrolidinas/efectos adversos , Tamoxifeno/efectos adversos , Adulto , Neoplasias de la Mama/tratamiento farmacológico , Femenino , Humanos , Persona de Mediana Edad , Nafoxidina/uso terapéutico , Recurrencia , Tamoxifeno/uso terapéuticoRESUMEN
39 women and 1 man have been monitored by sequential CEA, immunoglobulin, lymphocyte and monocyte readings, hydroxyproline excretion, scans and x-rays. CEA is shown to be a useful monitor of disease. The significance of the lymphocyte counts is discussed.
Asunto(s)
Neoplasias de la Mama/terapia , Propionibacterium acnes , Neoplasias de la Mama/sangre , Neoplasias de la Mama/inmunología , Antígeno Carcinoembrionario/análisis , Ensayos Clínicos como Asunto , Femenino , Hemoglobinas/análisis , Humanos , Inmunoglobulinas/análisis , Inmunoterapia/métodos , Recuento de Leucocitos , Activación de Linfocitos , Masculino , Pruebas CutáneasRESUMEN
A Phase I study of an immuno-chemotherapy regime was carried out using C. parvum as an immune-modulator. 14 women were studied. All received doses of C. parvum ranging from 2.5 mg to 21 mg administered in 1 litre of dextrose saline over 4 h. No evidence of tumour enhancement was observed.
Asunto(s)
Neoplasias de la Mama/terapia , Propionibacterium acnes , Adulto , Anciano , Neoplasias de la Mama/tratamiento farmacológico , Ensayos Clínicos como Asunto , Femenino , Humanos , Inmunoterapia/métodos , Persona de Mediana EdadRESUMEN
A survey was made of patients' reactions to high dose (21 mg) Corynebacterium parvum therapy given intravenously over four hours. The patients completed a pro forma. Rigors were the commonest side effect complained of being present in nearly all patients (24/25) and being very severe in one-third (10/25). Other problems were nausea (15/25), vomiting (17/25), bone pain (12/25) and headaches (12/25). One-third also usffered with other less common side effects. Overall, patients felt the side effects were as disagreeable as those experienced with outpatient chemotherapy.